1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Drugs In Development, 2022, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 21, 93, 98, 1, 10, 36 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 11, 1, 4 and 4 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Myelodysplastic Syndrome - Overview
- Myelodysplastic Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Myelodysplastic Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
- Myelodysplastic Syndrome - Drug Profiles
- Myelodysplastic Syndrome - Dormant Projects
- Myelodysplastic Syndrome - Discontinued Products
- Myelodysplastic Syndrome - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Myelodysplastic Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Myelodysplastic Syndrome - Dormant Projects, 2022
- Myelodysplastic Syndrome - Discontinued Products, 2022
- Number of Products under Development for Myelodysplastic Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AB Science SA
- AbbVie Inc
- Abfero Pharmaceuticals Inc
- Acrotech Biopharma LLC
- Actinium Pharmaceuticals Inc
- ADC Therapeutics SA
- Advanced BioDesign
- Affimed GmbH
- AIMM Therapeutics BV (Inactive)
- Akeso Inc
- Alaunos Therapeutics Inc
- ALX Oncology Holdings Inc
- Amgen Inc
- Amphivena Therapeutics Inc
- Angiocrine Bioscience Inc
- Apogenix AG
- Aprea Therapeutics Inc
- AptaBio Therapeutics Inc
- Aptevo Therapeutics Inc
- Arcellx Inc
- Argenx SE
- Ascentage Pharma Group International
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Aucentra Therapeutics Pty Ltd
- Aurigene Discovery Technologies Ltd
- Bayer AG
- BeiGene Ltd
- Beijing Mabworks Biotech Co Ltd
- Bellicum Pharmaceuticals Inc
- BerGenBio ASA
- Bio-Path Holdings Inc
- BioLineRx Ltd
- BioMed Valley Discoveries Inc
- BioSight Ltd
- BioTheryX Inc
- BlueSphere Bio Inc
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Captor Therapeutics SA
- CellCentric Ltd
- Cellenkos Inc
- Cellerant Therapeutics Inc
- Celularity Inc
- Celyad Oncology SA
- Center for Genetic Engineering and Biotechnology
- CheckPoint Immunology Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimeric Therapeutics Ltd
- Chimerix Inc
- China NT Pharma Group Co Ltd
- Chordia Therapeutics Inc
- Cleave Therapeutics Inc
- Cornerstone Pharmaceuticals Inc
- CrystalGenomics Inc
- Cullinan Oncology Inc
- Cyclacel Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Delta-Fly Pharma Inc
- Denovo Biopharma LLC
- Deverra Therapeutics Inc
- Diatheva srl
- DiNonA Inc
- Disc Medicine Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- Escend Pharmaceuticals Inc
- ExCellThera Inc
- Faron Pharmaceuticals Oy
- Fate Therapeutics Inc
- Forma Therapeutics Inc
- Fujifilm Holdings Corp
- Gadeta BV
- Gamida Cell Ltd
- GeneScience Pharmaceuticals Co Ltd
- Geron Corp
- Gilead Sciences Inc
- GSK plc
- GT Biopharma Inc
- Guangzhou Diqi Pharmaceutical Technology Co Ltd
- Hangzhou Bensheng Pharmaceutical Co Ltd
- Hangzhou Zede Pharmaceutical Technology Co Ltd
- HEC Pharma Co Ltd
- Helocyte Biosciences Inc
- HemoGenyx Pharmaceuticals Plc
- Horizon Therapeutics Plc
- Hutchison MediPharma Ltd
- HUYA Bioscience International LLC
- I-Mab
- iCell Gene Therapeutics LLC
- IGM Biosciences Inc
- Imago BioSciences Inc
- Immune System Key Ltd
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmunityBio Inc
- ImmunoGen Inc
- IN8bio Inc
- Incyte Corp
- Inmune Bio Inc
- Innate Pharma SA
- Innovent Biologics Inc
- Jasper Therapeutics Inc
- Jazz Pharmaceuticals Plc
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Lianhuan Pharmaceutical Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- KAHR medical Ltd
- Kangpu Biopharmaceuticals Ltd
- Karyopharm Therapeutics Inc
- Kiadis Pharma NV
- Kintor Pharmaceutical Ltd
- Kurome Therapeutics Inc
- LegoChem Biosciences Inc
- Les Laboratoires Servier SAS
- Leukos Biotech SL
- Lixte Biotechnology Holdings Inc
- Mabwell Shanghai Bioscience Co Ltd
- MacroGenics Inc
- Mana Therapeutics Inc
- Marker Therapeutics Inc
- Maxinovel Pharmaceuticals
- MediGene AG
- MedPacto Inc
- MEI Pharma Inc
- Mendus AB
- Merck & Co Inc
- Millennium Pharmaceuticals Inc
- Molecular Partners AG
- Molecular Templates Inc
- MorphoSys AG
- Nemucore Medical Innovations Inc
- Newave Pharmaceutical Inc
- Nkarta Inc
- Nohla Therapeutics Inc
- Novartis AG
- Ohara Pharmaceutical Co Ltd
- Oncoheroes Biosciences Inc
- Onconova Therapeutics Inc
- Oncotelic Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Orca Biosystems Inc
- Otsuka Pharmaceutical Co Ltd
- Oxcia AB
- PersImmune Inc
- Pfizer Inc
- Pharma Mar SA
- Pharmaxis Ltd
- Pinotbio Inc
- Plexxikon Inc
- Prelude Therapeutics Inc
- QLSF Biotherapeutics Inc
- Race Oncology Ltd
- Rigel Pharmaceuticals Inc
- Roivant Sciences Ltd
- Ryvu Therapeutics SA
- Salarius Pharmaceuticals Inc
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Shattuck Labs Inc
- Shorla Pharma Ltd
- Silence Therapeutics Plc
- Sino Biopharmaceutical Ltd
- SiNOPSEE Therapeutics Pte Ltd
- Smart Immune SAS
- Stelexis Therapeutics LLC
- Suzhou JiSheng Pharmaceutical Co Ltd
- Syntrix Pharmaceuticals
- Syros Pharmaceuticals Inc
- Tacitus Therapeutics Inc
- Takara Bio Inc
- TC BioPharm Ltd
- Teva Pharmaceutical Industries Ltd
- Toko Pharmaceutical Industries Co Ltd
- TOT Biopharm Co Ltd
- Treadwell Therapeutics Inc
- Trethera Corp
- TScan Therapeutics Inc
- Vincerx Pharma Inc
- Vyriad Inc
- Wugen Inc
- Xencor Inc
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zydus Lifesciences Ltd
